While the mechanism of action of bortezomib is different, bortezomib induces apoptosis in multiple myeloma cells and triggers immunogenic cell death (ICD), characterized by the exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity [13]. Here, CALR is linked to neoplasm.